Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Clin Nutr ESPEN. 2017 May 3;20:17–23. doi: 10.1016/j.clnesp.2017.04.004

Table 3.

Outcome measurements of 78 infants completing the study, Clinoleic® n = 37 and SMOFlipid® n = 41.

Clinoleic® SMOFlipid® p-value
BPD n (%) 17 (42) 22 (58) 0.18
NEC (%) 1 (3) 4 (10) 0.21
PDA (%) 29 (79) 25 (61) 0.08
Any ROP (%) 28 (78) 33 (80) 0.40
Severe ROP (%) 13 (35) 18 (44) 0.29
SEPSIS (%) 11 (30) 19 (46) 0.10
Cholestasis (%) 2 (5.7) 4 (9.8) 0.39
Weight change SDS mean (SD) (n = 65) −0.38 (1.2) −0.22 (1.1) 0.91
Height change SDS mean (SD) (n = 60) −1.62 (1.9) −0.75 (1.9) 0.25
Head circumference change mean (SD) (n = 58) −0.59 (1.2) −0.64 (1.4) 0.79

BPD: Bronchopulmonary dysplasia; NEC: Necrotizing enterocolitis; PDA, patent ductus arteriosus; Any ROP: Any stage of retinopathy of prematurity, Severe ROP: ROP stage 3 and or treated for ROP, SDS, standard deviation scores, SEPSIS: Sepsis verified by culture and or C-Reactive Protein. Chi-square and Mann–Whitney test used.